Bolt Biotherapeutics Inc reports results for the quarter ended in September - Earnings Summary

Bolt Biotherapeutics

10/11/2022 22:23

* Bolt Biotherapeutics Inc  BOLT.OQ  reported a quarterly
adjusted
loss of 58 cents​​ per share for the quarter ended in September.
The mean expectation of six analysts for the quarter was for a
loss of 56 cents per share.
    * Revenue rose 180.9% to $2.11 million from a year ago;
analysts
expected $984.60 thousand. 
    * Bolt Biotherapeutics Inc's reported EPS for the quarter
was a
loss of 58 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Bolt Biotherapeutics Inc shares had fallen by 13.5% this
quarter and lost 73.9% so far this year.
    * The company reported a quarterly loss of $21.76 million.
    * Wall Street's median 12-month price target for Bolt
Biotherapeutics Inc is $7.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 10:22 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.56          -0.58          Missed
 Jun. 30 2022      -0.68          -0.61          Beat
 Mar. 31 2022      -0.72          -0.64          Beat
 Dec. 31 2021      -0.82          -0.73          Beat